Gp100:209-217(210M) peptide vaccine (NCI)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGp100:209-217(210M) peptide vaccine (NCI)
Drug Alias Namegp100 melanoma-associated antigen vaccine
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionMelanocyte protein PMEL inhibitors
TargetsMelanocyte protein PMEL
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A